(VIANEWS) - Halozyme Therapeutics (HALO), Catalyst Pharmaceuticals (CPRX), Pacira BioSciences (PCRX) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Halozyme Therapeutics (HALO)
61.1% sales growth and 265.32% return on equity
Halozyme Therapeutics, Inc. is a platform for biopharmaceutical technology in the United States, Switzerland, Ireland, Belgium, Japan, Canada, and globally.
Halozyme Therapeutics's sales growth this year is expected to be 36.2% and 27% for next year.
Year-on-year quarterly revenue growth grew by 31.7%, now sitting on 471.57M for the twelve trailing months.
Volume
Today's last reported volume for Halozyme Therapeutics is 3186780 which is 198.49% above its average volume of 1067610.
Halozyme Therapeutics's sales growth is a negative 0% for the ongoing quarter and 61.1% for the next. The company's growth estimates for the present quarter and the next is a negative 24.2% and 5.5%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 265.32%.
Volatility
Halozyme Therapeutics's last day, last week, and last month's current intraday variation average was 0.21%, 1.71%, and 2.09%, respectively.
Halozyme Therapeutics's highest amplitude of average volatility was 3.83% (day), 3.00% (last week), and 3.50% (last month), respectively.
Halozyme Therapeutics's Stock Yearly Top and Bottom Value
Halozyme Therapeutics's stock is valued at $46.90 at 11:22 EST, below its 52-week high of $48.58 and way higher than its 52-week low of $31.36.
Halozyme Therapeutics's Moving Average
Halozyme Therapeutics's value is above its 50-day moving average of $43.31 and way above its 200-day moving average of $38.76.2. Catalyst Pharmaceuticals (CPRX)
54.1% sales growth and 20.98% return on equity
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical firm that focuses on the development and commercialization of therapies for individuals with neurological and rare neuromuscular diseases.
Catalyst Pharmaceuticals's sales growth this year is expected to be 42.6% and 15.4% for next year.
Year-on-year quarterly revenue growth grew by 23.5%, now sitting on 140.83M for the twelve trailing months.
Volume
Today's last reported volume for Catalyst Pharmaceuticals is 1283260 which is 9.77% above its average volume of 1169040.
Catalyst Pharmaceuticals's sales growth for the next quarter is 54.1%. The company's growth estimates for the ongoing quarter and the next is 54.5% and 90%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 20.98%.
Volatility
Catalyst Pharmaceuticals's last day, last week, and last month's current intraday variation average was 0.79%, 1.86%, and 2.32%, respectively.
Catalyst Pharmaceuticals's highest amplitude of average volatility was 4.59% (day), 4.16% (last week), and 4.56% (last month), respectively.
Catalyst Pharmaceuticals's Stock Yearly Top and Bottom Value
Catalyst Pharmaceuticals's stock is valued at $7.55 at 11:22 EST, way under its 52-week high of $8.65 and way above its 52-week low of $4.81.
Catalyst Pharmaceuticals's Moving Average
Catalyst Pharmaceuticals's value is above its 50-day moving average of $7.03 and above its 200-day moving average of $6.93.3. Pacira BioSciences (PCRX)
38.6% sales growth and 6.22% return on equity
Pacira BioSciences, Inc. offers non-opioid pain relief and regenerative healthcare solutions to health care professionals and patients throughout the United States.
Pacira BioSciences's sales growth this year is expected to be 30.2% and 15.7% for next year.
Year-on-year quarterly revenue growth grew by 21.5%, now sitting on 541.53M for the twelve trailing months.
Volume
Today's last reported volume for Pacira BioSciences is 460777 which is 14.58% below its average volume of 539487.
Pacira BioSciences's sales growth is a negative 0% for the ongoing quarter and 38.6% for the next. The company's growth estimates for the present quarter and the next is 11.7% and 30.6%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.22%.
Volatility
Pacira BioSciences's last day, last week, and last month's current intraday variation average was 2.04%, 2.21%, and 2.98%, respectively.
Pacira BioSciences's highest amplitude of average volatility was 3.05% (day), 3.97% (last week), and 4.31% (last month), respectively.
Pacira BioSciences's Stock Yearly Top and Bottom Value
Pacira BioSciences's stock is valued at $57.43 at 11:22 EST, way below its 52-week high of $82.16 and way above its 52-week low of $45.05.
Pacira BioSciences's Moving Average
Pacira BioSciences's worth is way below its 50-day moving average of $64.18 and under its 200-day moving average of $61.97.4. Allegiant Travel Company (ALGT)
31% sales growth and 14.19% return on equity
Allegiant Travel Company is a leisure travel agency that provides services and products for residents in underserved areas of the United States.
Allegiant Travel Company's sales growth this year is expected to be 37.8% and 12.1% for next year.
Year-on-year quarterly revenue growth grew by 79.2%, now sitting on 1.93B for the twelve trailing months.
Volume
Today's last reported volume for Allegiant Travel Company is 116357 which is 53.07% below its average volume of 247945.
Allegiant Travel Company's sales growth is a negative 0% for the ongoing quarter and 31% for the next. The company's growth estimates for the ongoing quarter and the next is a negative 37.6% and 72.7%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.19%.
Volatility
Allegiant Travel Company's last day, last week, and last month's current intraday variation average was 0.83%, 1.77%, and 2.99%, respectively.
Allegiant Travel Company's highest amplitude of average volatility was 3.08% (day), 3.93% (last week), and 4.72% (last month), respectively.
Allegiant Travel Company's Stock Yearly Top and Bottom Value
Allegiant Travel Company's stock is valued at $112.96 at 11:22 EST, way under its 52-week high of $215.48 and higher than its 52-week low of $109.82.
Allegiant Travel Company's Moving Average
Allegiant Travel Company's value is way below its 50-day moving average of $136.02 and way under its 200-day moving average of $166.26.5. Regional Management Corp. (RM)
24.2% sales growth and 30.89% return on equity
Regional Management Corp. is a multi-faceted consumer finance company that offers various installment loans to people who have limited credit access from credit cards companies or banks.
Regional Management Corp.'s sales growth this year is anticipated to be 17.7% and 11.2% for next year.
Year-on-year quarterly revenue growth grew by 24.1%, now sitting on 440.94M for the twelve trailing months.
Volume
Today's last reported volume for Regional Management Corp. is 15206 which is 60.52% below its average volume of 38521.
Regional Management Corp.'s sales growth for the next quarter is 24.2%. The company's growth estimates for the current quarter and the next is a negative 46% and negative -12.8%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 30.89%.
Volatility
Regional Management Corp.'s last day, last week, and last month's current intraday variation average was 0.53%, 2.36%, and 2.59%, respectively.
Regional Management Corp.'s highest amplitude of average volatility was 2.98% (day), 4.76% (last week), and 3.83% (last month), respectively.
Regional Management Corp.'s Stock Yearly Top and Bottom Value
Regional Management Corp.'s stock is valued at $37.92 at 11:22 EST, way below its 52-week high of $67.60 and above its 52-week low of $37.02.
Regional Management Corp.'s Moving Average
Regional Management Corp.'s worth is way under its 50-day moving average of $42.72 and way below its 200-day moving average of $50.77.6. Terreno Realty Corporation (TRNO)
21.2% sales growth and 4.92% return on equity
Terreno Realty Corp. and its subsidiaries, A"CompanyA"), acquire, own and operate industrial real estate in six major U.S. coastal markets: Los Angeles, Northern New Jersey/New York City, San Francisco Bay Area, Seattle, Miami, Washington, D.C.
Terreno Realty Corporation's sales growth this year is anticipated to be 17.6% and 8.4% for next year.
Year-on-year quarterly revenue growth grew by 26.3%, now sitting on 235.27M for the twelve trailing months.
Volume
Today's last reported volume for Terreno Realty Corporation is 297418 which is 34.92% below its average volume of 457018.
Terreno Realty Corporation's sales growth for the next quarter is 21.2%. The company's growth estimates for the present quarter and the next is 8% and negative -3.3%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.92%.
Volatility
Terreno Realty Corporation's last day, last week, and last month's current intraday variation average was 0.85%, 1.07%, and 1.60%, respectively.
Terreno Realty Corporation's highest amplitude of average volatility was 2.16% (day), 2.50% (last week), and 2.51% (last month), respectively.
Terreno Realty Corporation's Stock Yearly Top and Bottom Value
Terreno Realty Corporation's stock is valued at $56.44 at 11:22 EST, way below its 52-week high of $86.00 and higher than its 52-week low of $54.51.
Terreno Realty Corporation's Moving Average
Terreno Realty Corporation's worth is below its 50-day moving average of $61.30 and way below its 200-day moving average of $70.62.7. Ball Corporation (BLL)
13.7% sales growth and 26.61% return on equity
Ball Corporation provides aluminum packaging products for the personal care, beverage, automobile, paint and healthcare industries.
Ball Corporation's sales growth this year is expected to be 15.6% and 8.3% for next year.
Year-on-year quarterly revenue growth grew by 23.5%, now sitting on 12.78B for the twelve trailing months.
Volume
Today's last reported volume for Ball Corporation is 2934840 which is 43.58% above its average volume of 2043980.
Ball Corporation's sales growth for the next quarter is 13.7%. The company's growth estimates for the ongoing quarter and the next is 12.4% and 22.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 26.61%.
Volatility
Ball Corporation's last day, last week, and last month's current intraday variation average was 2.62%, 1.92%, and 1.74%, respectively.
Ball Corporation's highest amplitude of average volatility was 3.09% (day), 3.01% (last week), and 3.30% (last month), respectively.
Ball Corporation's Stock Yearly Top and Bottom Value
Ball Corporation's stock is valued at $69.49 at 11:22 EST, way below its 52-week low of $77.95.
Ball Corporation's Moving Average
Ball Corporation's value is way under its 50-day moving average of $92.41 and way under its 200-day moving average of $88.47.8. Everspin Technologies (MRAM)
6.5% sales growth and 27.92% return on equity
Everspin Technologies, Inc. produces and sells magneticoresistive random-access memory (MRAM), products throughout the United States, Hong Kong, Japan, China, Germany, China, Germany, as well as internationally.
Everspin Technologies's sales growth this year is expected to be 8.6% and 14.3% for next year.
Year-on-year quarterly revenue growth grew by 39.6%, now sitting on 59.21M for the twelve trailing months.
Volume
Today's last reported volume for Everspin Technologies is 122020 which is 8.24% below its average volume of 132985.
Everspin Technologies's sales growth for the next quarter is 6.5%. The company's growth estimates for the present quarter and the next is a negative 100% and negative -55.6%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 27.92%.
Volatility
Everspin Technologies's last day, last week, and last month's current intraday variation average was 3.76%, 3.03%, and 2.67%, respectively.
Everspin Technologies's highest amplitude of average volatility was 5.92% (day), 6.09% (last week), and 5.02% (last month), respectively.
Everspin Technologies's Stock Yearly Top and Bottom Value
Everspin Technologies's stock is valued at $5.05 at 11:22 EST, way below its 52-week high of $14.36 and higher than its 52-week low of $4.90.